NCT03822884View on ClinicalTrials.gov

Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions

Anemia

Interventions

DRUG

Epoetin Alfa 40000 UNT/ML

40.000 UI subcutaneous single dose

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bio Sidus SA

INDUSTRY